DrugPatentWatch Database Preview
Pfizer Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and thirty-seven approved drugs.
There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand two hundred and eighty-seven patent family members on PFIZER drugs in seventy-six countries and two hundred and twenty-one supplementary protection certificates in eighteen countries.
Summary for Pfizer
| International Patents: | 1287 |
| US Patents: | 48 |
| Tradenames: | 104 |
| Ingredients: | 98 |
| NDAs: | 137 |
| Drug Master File Entries: | 3 |
| Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
| PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | Yes | 7,842,699 | Start Trial | Start Trial | ||||
| Pfizer Inc | TROXYCA ER | naltrexone hydrochloride; oxycodone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 207621-004 | Aug 19, 2016 | DISCN | No | No | 8,685,443 | Start Trial | Start Trial | ||||
| Pfizer | NAVANE | thiothixene | CAPSULE;ORAL | 016584-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-001 | Dec 30, 1993 | 4,894,476*PED | Start Trial |
| Pfizer | EXUBERA | insulin recombinant human | POWDER;INHALATION | 021868-002 | Jan 27, 2006 | 6,685,967 | Start Trial |
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-001 | Nov 19, 1991 | 4,743,450*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Tablets | 0.6 mg | ➤ Subscribe | 2011-12-29 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2009-04-07 |
| ➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2004-10-25 |
| ➤ Subscribe | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | ➤ Subscribe | 2005-10-19 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 150 mg and 200 mg | ➤ Subscribe | 2005-11-09 |
| ➤ Subscribe | Tablets | 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg | ➤ Subscribe | 2006-12-29 |
| ➤ Subscribe | Tablets | 2.5 mg/40 mg | ➤ Subscribe | 2009-09-17 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2004-11-19 |
| ➤ Subscribe | Tablets | 20 mg and 40 mg | ➤ Subscribe | 2010-03-29 |
Premature patent expirations for PFIZER
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Pfizer Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5717824 | Start Trial |
| China | 101855232 | Start Trial |
| Japan | 2013540158 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0245997 | C300002 | Netherlands | Start Trial | PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129 |
| 1077912 | CA 2007 00046 | Denmark | Start Trial | PRODUCT NAME: FESOTERODIN, FUMARAT |
| 2603514 | CA 2019 00015 | Denmark | Start Trial | PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
